Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
The classification of Opioid-Induced Constipation includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol and other OTC drugs. The revenue proportion of Lubiprostone in 2017 is about 33%, and the proportion of OTC drugs is in about 34%.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
According to this study, over the next five years the Opioid-Induced Constipation market will register a 4.4% CAGR in terms of revenue, the global market size will reach US$ 2770 million by 2024, from US$ 2240 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Opioid-Induced Constipation business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.
This study considers the Opioid-Induced Constipation value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Opioid-Induced Constipation consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
Focuses on the key global Opioid-Induced Constipation manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Opioid-Induced Constipation with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Opioid-Induced Constipation submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
